Distinguishing among these possibilities has been difficult as the developmental course of NeoAg-specific CD4+ T cells responding to progressive tumor growth in vivo is largely unknown in terms of phenotype, magnitude, and TCR repertoire. This evidence concerns the gene CD4 and neoplasm.